Signal
Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal for in vivo cell therapy
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-04-20 14:18 UTCUpdated 2026-04-21 00:16 UTC
redditrss
clinical_trialsdrug_developmentbiotech_fundingr_and_dfda
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Eli Lilly is expanding its in vivo cell therapy portfolio with the acquisition of Kelonia Therapeutics, a company developing a phase 1-stage CAR-T therapy targeting multiple myeloma. The deal, valued at up to $7 billion with $3.25 billion paid upfront, represents Lilly's second acquisition in this space this year. This move underscores Lilly's commitment to advancing innovative cancer treatments through early-stage cell therapy development.
Entities
Eli LillyKelonia Therapeutics
Score total
1.56
Momentum 24h
3
Posts
3
Origins
3
Source types
2
Duplicate ratio
0%
Why now
- Kelonia's therapy is in early-phase clinical trials, making it a timely acquisition.
- Lilly is accelerating its investment in innovative cancer treatments this year.
- The deal follows Lilly's recent acquisition of another in vivo cell therapy company, signaling a trend.
Why it matters
- Strengthens Lilly's position in the emerging in vivo CAR-T therapy field.
- Targets multiple myeloma, a cancer with significant unmet medical need.
- Highlights Lilly's strategic focus on early-stage cell therapy development.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to advance in vivo CAR-T therapy for multiple myeloma.
How sources frame it
- BioPharma Dive: neutral
- Fierce Biotech: neutral
- CNBC: neutral
All evidence
All evidence
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
biotech · cnbc.com · 2026-04-21 00:16 UTC
Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout
BioPharma Dive · biopharmadive.com · 2026-04-20 15:14 UTC
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy.
Fierce Biotech · fiercebiotech.com · 2026-04-20 14:18 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- biotech (1)
- BioPharma Dive (1)
- Fierce Biotech (1)
Top origin domains (this list)
- cnbc.com (1)
- biopharmadive.com (1)
- fiercebiotech.com (1)